{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:05:49Z","timestamp":1784765149228,"version":"3.55.0"},"reference-count":21,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2014,8,31]]},"abstract":"<jats:p>Interleukin-21 (IL-21) plays an important role in the pathogenesis of rheumatoid arthritis (RA). The aim of our study was to assess serum levels of IL-21 in patients with recent-onset RA in relation to disease activity and response to treatment. We analyzed serum levels of IL-21 in 51 RA patients, both before and 12 weeks after the initiation of treatment and in 36 healthy individuals. Disease activity was assessed at baseline and at weeks 12 and 24 using the Disease Activity Score for 28 joints, serum levels of C-reactive protein, and the total swollen joint count. We found that IL-21 levels were not increased in patients with recent-onset RA compared with healthy controls, but they had significantly decreased from baseline to week 12 during treatment. Baseline levels of IL-21 significantly correlated with measures of disease activity (p&lt;0.02 for all). Although IL-21 levels did not predict achievement of remission, decrease in IL-21 levels correlated with improvement in disease activity after 12 weeks (p&lt;0.02) and also after 24 weeks (p&lt;0.04) of treatment. Our data suggest that circulating IL-21 levels may serve as a biomarker of disease activity and better outcome in early phase of RA.<\/jats:p>","DOI":"10.33549\/physiolres.932701","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T13:56:49Z","timestamp":1604411809000},"page":"475-481","source":"Crossref","is-referenced-by-count":16,"title":["Decrease in Serum Interleukin-21 Levels Is Associated With Disease Activity Improvement in Patients With Recent-Onset Rheumatoid Arthritis"],"prefix":"10.33549","author":[{"given":"O.","family":"SGLUNDA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. F.","family":"MANN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"HULEJOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"PECHA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"PLE\u0160TILOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"R\u016e\u017dI\u010cKOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"FOJT\u00cdKOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"\u0160L\u00c9GLOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160.","family":"FOREJTOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"PAVELKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"VENCOVSK\u00dd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"\u0160ENOLT","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology and Clinic of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2014,8,17]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"ALETAHA D, NEOGI T, SILMAN AJ, FUNOVITS J, FELSON DT, BINGHAM CO 3RD, BIRNBAUM NS, BURMESTER GR, BYKERK VP, COHEN MD, COMBE B, COSTENBADER KH, DOUGADOS M, EMERY P, FERRACCIOLI G, HAZES JM, HOBBS K, HUIZINGA TW, KAVANAUGH A, KAY J, KVIEN TK, LAING T, MEASE P, M\u00c9NARD HA, MORELAND LW, NADEN RL, PINCUS T, SMOLEN JS, STANISLAWSKA-BIERNAT E, SYMMONS D, TAK PP, UPCHURCH KS, VENCOVSKY J, WOLFE F, HAWKER G: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-1588, 2010.","DOI":"10.1136\/ard.2010.138461"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"ANDR\u00c9S CEREZO L, MANN H, PECHA O, PLE\u0160TILOV\u00c1 L, PAVELKA K, VENCOVSK\u00dd J, SENOLT L: Decreases in serum levels of S100A8\/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 13: R122, 2011.","DOI":"10.1186\/ar3426"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"BRENNAN FM, MCINNES IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545, 2008.","DOI":"10.1172\/jci36389"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"CHEN DY, CHEN YM, CHEN HH, HSIEH CW, LIN CC, LAN JL: Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy. Arthritis Res Ther 13: R126, 2011.","DOI":"10.1186\/ar3431"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"GOTTENBERG JE, DAYER JM, LUKAS C, DUCOT B, CHIOCCHIA G, CANTAGREL A, SARAUX A, ROUX-LOMBARD P, MARIETTE X: Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 71: 1243-1248, 2012.","DOI":"10.1136\/annrheumdis-2011-200975"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"J\u00dcNGEL A, DISTLER JH, KUROWSKA-STOLARSKA M, SEEMAYER CA, SEIBL R, FORSTER A, MICHEL BA, GAY RE, EMMRICH F, GAY S, DISTLER O: Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 50: 1468-1476, 2004.","DOI":"10.1002\/art.20218"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"KWOK SK, CHO ML, PARK MK, OH HJ, PARK JS, HER YM, LEE SY, YOUN J, JU JH, PARK KS, KIM SI, KIM HY, PARK SH: Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum 64: 740-751, 2012.","DOI":"10.1002\/art.33390"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"MCINNES IB, O'DELL JR: State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 69: 1898-1906, 2010.","DOI":"10.1136\/ard.2010.134684"},{"key":"ref8","unstructured":"MONTELEONE G, SARRA M, PALLONE F: Interleukin-21 in T cell-mediated diseases. Discov Med 8: 113-117, 2009."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"MOURA RA, CASC\u00c3O R, PERP\u00c9TUO I, CANH\u00c3O H, VIEIRA-SOUSA E, MOUR\u00c3O AF, RODRIGUES AM, POLIDO-PEREIRA J, QUEIROZ MV, ROS\u00c1RIO HS, SOUTO-CARNEIRO MM, GRACA L, FONSECA JE: Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford) 50: 278-282, 2011.","DOI":"10.1093\/rheumatology\/keq338"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"NIU X, HE D, ZHANG X, YUE T, LI N, ZHANG JZ, DONG C, CHEN G: IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 71: 334-341, 2010.","DOI":"10.1016\/j.humimm.2010.01.010"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"OZAKI K, SPOLSKI R, FENG CG, QI CF, CHENG J, SHER A, MORSE HC 3RD, LIU C, SCHWARTZBERG PL, LEONARD WJ: A critical role for IL-21 in regulating immunoglobulin production. Science 298: 1630-1634, 2002.","DOI":"10.1126\/science.1077002"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"PARRISH-NOVAK J, DILLON SR, NELSON A, HAMMOND A, SPRECHER C, GROSS JA, JOHNSTON J, MADDEN K, XU W, WEST J, SCHRADER S, BURKHEAD S, HEIPEL M, BRANDT C, KUIJPER JL, KRAMER J, CONKLIN D, PRESNELL SR, BERRY J, SHIOTA F, BORT S, HAMBLY K, MUDRI S, CLEGG C, MOORE M, GRANT FJ, LOFTON-DAY C, GILBERT T, RAYOND F, CHING A, YAO L, SMITH D, WEBSTER P, WHITMORE T, MAURER M, KAUSHANSKY K, HOLLY RD, FOSTER D: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63, 2000.","DOI":"10.1038\/35040504"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"RASMUSSEN TK, ANDERSEN T, HVID M, HETLAND ML, H\u00d8RSLEV-PETERSEN K, STENGAARD-PEDERSEN K, HOLM CK, DELEURAN B: Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 37: 2014-2020, 2010.","DOI":"10.3899\/jrheum.100259"},{"key":"ref14","unstructured":"SALEEM B, NIZAM S, EMERY P: Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 24: 33-36, 2006."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"SCOTT DL, WOLFE F, HUIZINGA TW: Rheumatoid arthritis. Lancet 376: 1094-1108, 2010.","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"SENOLT L, VENCOVSK\u00dd J, PAVELKA K, OSPELT C, GAY S: Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 9: 102-107, 2009.","DOI":"10.1016\/j.autrev.2009.03.010"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"SMOLEN JS, ALETAHA D, BIJLSMA JW, BREEDVELD FC, BOUMPAS D, BURMESTER G, COMBE B, CUTOLO M, DE WIT M, DOUGADOS M, EMERY P, GIBOFSKY A, GOMEZ-REINO JJ, HARAOUIB, KALDEN J, KEYSTONE EC, KVIEN TK, MCINNES I, MARTIN-MOLA E, MONTECUCCO C, SCHOELS M, VAN DER HEIJDE D; T2T Expert Committee: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631-637, 2010.","DOI":"10.1136\/ard.2009.123919"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"VAN GESTEL AM, HAAGSMA CJ, VAN RIEL PL: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41: 1845-1850, 1998.","DOI":"10.1002\/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"YOUNG DA, HEGEN M, MA HL, WHITTERS MJ, ALBERT LM, LOWE L, SENICES M, WU PW, SIBLEY B, LEATHURBY Y, BROWN TP, NICKERSON-NUTTER C, KEITH JC JR, COLLINS M: Blockade of the interleukin-21\/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 56: 1152-1163, 2007.","DOI":"10.1002\/art.22452"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"ZIVOJINOVIC SM, PEJNOVIC NN, SEFIK-BUKILICA MN, KOVACEVIC LV, SOLDATOVIC II, DAMJANOV NS: Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis. J Rheumatol 39: 18-21, 2012.","DOI":"10.3899\/jrheum.110697"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T13:57:00Z","timestamp":1604411820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/63\/63_475.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,17]]},"references-count":21,"URL":"https:\/\/doi.org\/10.33549\/physiolres.932701","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8,17]]}}}